Evidence map›Paper›PMID 20158441›Full record

ArticleAssay and drug development technologies2010

Development and validation of a transcreener assay for detection of AMP- and GMP-producing enzymes.

Matt Staeben, Karen M Kleman-Leyer, Andrew L Kopp, Thane A Westermeyer, Robert G Lowery

Open access · greenAbstract read
In one paragraph

Article in Assay and drug development technologies, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 30 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Matt StaebenBellBrook Labs, Madison, Wisconsin, USA. matt.staeben@bellbrooklabs.com
Karen M Kleman-Leyer
Andrew L Kopp
Thane A Westermeyer
Robert G Lowery
Bellbrook Labs (United States) · US

Funding

Generic Fluorescent HTS Assay for Kinases and ATPasesR44CA110535 · NCI · BELLBROOK LABS, LLC · PI LOWERY, ROBERT G · 2006 to 2007
$648k
NCI NIH HHS 5R44CA110535
6 · The paper itself

Abstract

Screening of AMP- and GMP-producing enzymes such as phosphodiesterases (PDEs), ligases, and synthetases would be simplified by the ability to directly detect unmodified nucleoside monophosphates. To address this need, we developed polyclonal and monoclonal antibodies that recognize AMP and GMP with nanomolar sensitivity and high selectivity vs. the corresponding triphosphate and 3',5'-cyclic monophosphate nucleotides that serve as substrates for many enzymes in these classes. One of these antibodies was used to develop a Transcreener AMP/GMP assay with a far red fluorescence polarization (FP) readout. This polyclonal antibody exhibited extremely high selectivity, with IC(50) ratios of 6,000 for ATP/AMP, 3,810 for cAMP/AMP, and 6,970 for cGMP/GMP. Standard curves mimicking enzymatic conversion of cAMP, cGMP, and ATP to the corresponding monophosphates yielded Z' values of >0.85 at 10% conversion. The assay reagents were shown to be stable for 24 h at room temperature, both before and after dispensing. The Transcreener AMP/GMP FP assay was used for enzymatic detection of cGMP- and cAMP-dependent PDEs 4A1A, 3A, and 9A2 and ATP-dependent ligases, acetyl CoA synthetase, and ubiquitin- activating enzyme (UBE1). Shifts of >100 mP were observed in the linear part of the progress curves for all enzymes tested, and the PDE isoforms exhibited the expected substrate and inhibitor selectivity. These studies demonstrate that direct immunodetection of AMP and GMP is a flexible, robust enzyme assay method for diverse AMP- and GMP-producing enzymes. Moreover, it eliminates many of the shortcomings of other methods including the need for fluorescently labeled substrates, the low signal:background inherent in substrate depletion assays, and the potential for interference with coupling enzymes.

Indexed as

3',5'-Cyclic-AMP PhosphodiesterasesAcetyl-CoA C-AcetyltransferaseAdenosine MonophosphateAdenosine TriphosphateAlgorithmsBinding, CompetitiveCyclic AMPCyclic GMPDrug Evaluation, PreclinicalEnzyme InhibitorsFluorescence PolarizationGuanosine MonophosphateHumansIndicators and ReagentsNADReference Standards3',5'-Cyclic-AMP PhosphodiesterasesAcetyl-CoA C-AcetyltransferaseAdenosine MonophosphateAdenosine TriphosphateCyclic AMPCyclic GMPEnzyme InhibitorsGuanosine MonophosphateIndicators and ReagentsNADUBE2H protein, humanUbiquitin-Activating EnzymesUbiquitin-Conjugating Enzymes

Identifiers

PMID20158441
PMCPMC2894640
OpenAlexW2016307200

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.